{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
aminosalicylic acid
to a specific field?
Status:
Investigational
Source:
INN:tizoprolic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Tizoprolic acid is an anti-lipolytic drug, a blood ketone lowering agent.
Status:
Investigational
Source:
INN:flutomidate [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Flutomidate was studied as a hypnotic agent. Information about the current use of this agent is not available.
Class (Stereo):
CHEMICAL (MIXED)
Rosaprostol is an antiulcer drug. This compound acts on the mucosal barrier in the stomach, preventing a drop in pH. More specifically, rosaprostol exhibits gastric antisecretory activity and cytoprotective action. Importantly, it does not have the undesired side effects (such as diarrhea and uterine stimulation) of other prostanoids. Rosaprostol was found to antagonize gastric acid output induced by NSAID administration and to prevent and treat the digestive disorders that resulted from taking NSAIDs. Furthermore, symptoms in patients with gastritis disappeared after administration of rosaprostol, and the drug was well-tolerated. Positive effects of rosaprostol were also reported in patients with duodenal ulcer. Several stereoisomers of rosaprostol have been synthesized.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nixylic acid, an anilinonicotinic acid derivative, is an anti-inflammatory agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cyheptropine is a tropine ester of dibenzo[a,d]cycloheptadiene-5-carboxylic acid, developed as an antiarrhythmic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Xanoxic acid was developed as a bronchodilator that has never been marketed. Information about the current use of this agent is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mespirenone (ZK 94679, 15β,16β-methylene-spironolactone) is a steroid aldosterone antagonist. In addition, it is a quite specific inhibitor of adrenocortical mineralocorticoid synthesis. In rodents mespirenone effectively prevents aldosterone-induced hypertension. It exerts natriuretic efficacy. Although it reached phase II clinical trials, it was discontinued in 1989.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cis-isomer of loxanast (IG-10) or 1-methyl-4-isohexylcyclohexane carboxylic acid has been reported as an inhibitor of delayed hypersensitivity reaction in animal models. It inhibited macrophage chemotaxis.
Status:
Investigational
Source:
NCT01215747: Phase 3 Interventional Completed Amyloidosis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Eprodisate (1,3-propanedisulfonate) is a negatively charged, sulfonated molecule of low molecular weight that has structural similarities to heparin sulfate; it is a glycosaminoglycan mimetic that binds to the glycosaminoglycan (GAG) binding site on serum A amyloid (AA) to prevent its interaction with glycosaminoglycan and arrest amyloidosis, or inhibit amyloid deposition. In nonclinical toxicity studies in two animal species (i.e., rat and dog), eprodisate was administered orally at doses of up to 2000 mg/kg/day for 39 weeks: eprodisate showed low toxicity potential at doses several fold higher than the anticipated clinical dose, was well tolerated upon chronic exposure and was found to be nonmutagenic and nonclastogenic. Furthermore, a series of safety pharmacology studies showed that eprodisate does not have any clinically
significant effect on major organ function.
Status:
Investigational
Source:
NCT01507194: Phase 2 Interventional Completed Postoperative Nausea and Vomiting
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vestipitant, also known as GW597599, is a neurokinin1 receptor antagonist that was being developed by GlaxoSmithKline for the treatment of postoperative nausea and vomiting. Vestipitant is one of the most potent and selective NK(1) receptor antagonists ever discovered, showing appropriate pharmacokinetic properties and in vivo activity. Its actions support the utility of NK(1) receptor blockade in the alleviation of anxiety and, possibly, depression. It was under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia. Vestipitant was shown to improve sleep maintenance in patients with primary insomnia, with no associated next-day cognitive impairment. The effects on wake after sleep onset and total sleep time were maintained following repeated dosing. Vestipitant has anxiolytic properties and a good safety profile. Vestipitant was investigated for potential effect against chronic tinnitus as a stand-alone treatment and in conjunction with a selective serotonin reuptake inhibitor, paroxetine. Although well-tolerated vestipitant, alone or in combination with paroxetine, was not effective in ameliorating tinnitus in this patient group.
